Transfusion Dependent Thalassemia clinical trials

Explore recruiting transfusion dependent thalassemia clinical trials.

Recruiting transfusion dependent thalassemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Transfusion Dependent Thalassemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia

Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE-T)

France, Netherlands, Italy, Germany, Denmark, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha or Beta Thalassemia (ENERGIZE)

Greece, Netherlands, Bulgaria, Denmark, Spain, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Improvement of MRI assessed cerebral Perfusion and oxygenation by luspatercept-induced Anemia Correction in non-transfusion dependent Thalassemia

Netherlands

Phase III and phase IV (Integrated) EU CTIS Study details

A Long-term Follow-up Study of Subjects with β-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)

Belgium, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

Greece, Italy, Germany, Spain, France, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Transfusion Dependent Thalassemia trials by city

Transfusion Dependent Thalassemia in Toronto Transfusion Dependent Thalassemia in Vancouver Transfusion Dependent Thalassemia in Montreal Transfusion Dependent Thalassemia in Calgary Transfusion Dependent Thalassemia in Edmonton Transfusion Dependent Thalassemia in Ottawa Transfusion Dependent Thalassemia in Winnipeg Transfusion Dependent Thalassemia in Quebec City Transfusion Dependent Thalassemia in Hamilton Transfusion Dependent Thalassemia in Kitchener Transfusion Dependent Thalassemia in London Transfusion Dependent Thalassemia in Halifax Transfusion Dependent Thalassemia in New York Transfusion Dependent Thalassemia in Los Angeles Transfusion Dependent Thalassemia in Chicago Transfusion Dependent Thalassemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease